CN116813614A - Prafloxacin hydrochloride dihydrate crystal and preparation method thereof - Google Patents

Prafloxacin hydrochloride dihydrate crystal and preparation method thereof Download PDF

Info

Publication number
CN116813614A
CN116813614A CN202310634032.6A CN202310634032A CN116813614A CN 116813614 A CN116813614 A CN 116813614A CN 202310634032 A CN202310634032 A CN 202310634032A CN 116813614 A CN116813614 A CN 116813614A
Authority
CN
China
Prior art keywords
prafloxacin
degrees
hydrochloride dihydrate
product
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310634032.6A
Other languages
Chinese (zh)
Inventor
郝红勋
李文磊
刘爱玲
黄欣
李守军
王娜
李亚玲
王霆
徐昭
周丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RINGPU (TIANJIN) BIO-PHARMACY CO LTD
Tianjin University
Original Assignee
RINGPU (TIANJIN) BIO-PHARMACY CO LTD
Tianjin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RINGPU (TIANJIN) BIO-PHARMACY CO LTD, Tianjin University filed Critical RINGPU (TIANJIN) BIO-PHARMACY CO LTD
Priority to CN202310634032.6A priority Critical patent/CN116813614A/en
Publication of CN116813614A publication Critical patent/CN116813614A/en
Pending legal-status Critical Current

Links

Abstract

The invention relates to a pramipexole dihydrochloride crystal form dihydrate, which is characterized in that the crystal X-ray powder diffraction pattern has characteristic peaks at diffraction angles 2θ=6.9+/-0.2 degrees, 7.6+/-0.2 degrees, 9.7+/-0.2 degrees, 12.4+/-0.2 degrees, 14.0+/-0.2 degrees, 15.6+/-0.2 degrees, 21.9+/-0.2 degrees and 29.0+/-0.2 degrees, and the crystal X-ray powder diffraction pattern has a powdery appearance. The preparation method comprises dissolving a certain amount of prafloxacin solid in water at room temperature, adding a certain amount of hydrochloric acid, magnetically stirring, keeping the temperature of the solution to 25 ℃, and keeping the temperature for 2-4 hours under the condition until crystals are separated out; filtering the product, and placing the obtained crystal in a drying oven at 40 ℃ for drying; and drying to obtain the final prafloxacin hydrochloride dihydrate product. The invention has stable process, simple operation, less energy consumption, more than 90 percent of crystal form product yield and more than 99 percent of product purity, and is suitable for manufacturing and long-term storage of pharmaceutical preparations.

Description

Prafloxacin hydrochloride dihydrate crystal and preparation method thereof
Technical Field
The invention belongs to the technical field of medicine separation, and particularly relates to a prafloxacin hydrochloride dihydrate crystal form and a crystallization preparation method thereof.
Background
Prafloxacin hydrochloride (Pradofloxacin hydrochloride) with chemical formula of C 21 H 22 FClN 4 O 3 The relative molecular weight is 432.88, the chemical name is 8-cyano-1-cyclopropyl-7- (1S, 6S-2, 8-diazabicyclo [ 4.3.0)]Nonan-8-yl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride having a structure shown in the following figure. The commercial product is light yellow powder, is easy to dissolve in water, has small solubility in most organic solvents, is not yet popularized in China, and belongs to a new medicine development stage.
Prafloxacin hydrochloride (pradofloxacin hydrochloride) is a new third-generation fluoroquinolone antibacterial agent special for animals, developed by German Bayer company, with the trade name Veraflox hydrochloride, and is used for treating bacterial infection of dogs and cats, the quinolone antibacterial agent mainly inhibits the A subunit of DNA rotary chemical book enzyme (also called topoisomerase II), and only a few medicines also act on the B subunit, so that the activity of the antibacterial agent is destroyed, the synthesis of deoxyribonucleic acid, ribonucleic acid and protein is interfered, and bacteria can not split any more, thereby playing a role in sterilization. Compared with the existing fluoroquinolone antibacterial agents, the prafloxacin hydrochloride has enhanced antibacterial activity on gram-positive bacteria and anaerobic pathogenic bacteria and has wider antibacterial effect.
Polymorphism is a common phenomenon of drug molecules, and different crystal forms can show different physicochemical properties so as to influence the curative effect of the drug. The prafloxacin hydrochloride solid sold in the market at present only has the prafloxacin hydrochloride and the prafloxacin hemihydrochloride, and has the problems of complex process, poor stability and the like, so that the prafloxacin hydrochloride is necessary to be subjected to polymorphic research and the dominant crystal form is screened.
Disclosure of Invention
The invention provides prafloxacin hydrochloride dihydrate and a crystal preparation method of the dihydrate.
The X-ray powder diffraction pattern of the prafloxacin hydrochloride dihydrate crystal provided by the invention has characteristic peaks at diffraction angles 2θ=6.9+/-0.2°, 7.6+/-0.2 °, 9.7+/-0.2 °, 12.4+/-0.2 °, 14.0+/-0.2 °, 15.6+/-0.2 °, 21.9+/-0.2 ° and 29.0+/-0.2 ° as shown in fig. 1.
Preferably, the prafloxacin hydrochloride dihydrate crystal has a molecular formula of C 21 H 26 FClN 4 O 5
Any of the above is preferred, wherein the prafloxacin hydrochloride dihydrate crystals are desolvated at 60 ℃. As shown in figure 2, a DSC profile of the prafloxacin hydrochloride dihydrate crystals showing desolvation at 60 ℃.
The invention also provides a preparation method of the prafloxacin hydrochloride dihydrate crystal, which comprises the following steps:
step 1: dissolving prafloxacin solids in water and/or ethanol until clear;
step 2: keeping the temperature of the solution obtained in the step 1 constant, and adding hydrochloric acid into the solution obtained in the step 1;
step 3: growing crystal at constant temperature;
step 4: and (3) drying the product obtained in the step (3) to obtain the final prafloxacin hydrochloride dihydrate product.
Preferably, the concentration of the prafloxacin solution after dissolution in the step 1 is 0.05-0.15 g/ml.
In step 2, the hydrochloric acid is preferably added at a rate of 1ml/min to 4ml/min.
In any of the above steps, the constant temperature in step 2 is preferably 25 to 30 ℃.
In step 3, the crystal growth time is preferably 2 to 4 hours
In any of the above steps, the crystal growth temperature is preferably 25 to 30 ℃.
In any one of the above preferred steps, in step 4, the product obtained in step 3 is filtered, and the obtained crystals are dried in a drying oven; and drying to obtain the final prafloxacin hydrochloride dihydrate product.
In any of the above steps, it is preferable that the drying temperature is 40 to 45℃and the drying time is 2 to 4 hours in step 4.
Any one of the above is preferable, and the specific steps are as follows:
(1) Dissolving a certain amount of prafloxacin solid in water or ethanol and methanol at room temperature, and magnetically stirring to clarify the prafloxacin solid; preferably, the concentration of the prafloxacin aqueous solution or the ethanol solution is 0.05-0.15 g/ml;
(2) Keeping the temperature of the solution to 25 ℃ and keeping the temperature, and adding a certain amount of hydrochloric acid into the solution at a feeding rate of 1 ml/min-4 ml/min;
(3) Stirring for 2-4 h at constant temperature under the condition until crystals are separated out;
(4) Filtering the product, and carrying out vacuum suction filtration;
(5) Placing the obtained crystal in a drying oven at 40 ℃ for drying;
(6) And drying to obtain the final prafloxacin hydrochloride dihydrate.
In the method, the crystallization mode is reaction crystallization.
The invention examines the chemical stability of the prepared prafloxacin hydrochloride dihydrate crystal, and the color, purity and morphology of the crystal form are not changed in the period of 30 days of storage under the conditions of 30 ℃ +/-5 ℃ and 40+/-5% RH, thus indicating that the crystal form has good chemical stability. The examination results are shown in Table 1.
Table 1 table of examination of chemical stability of prafloxacin hydrochloride dihydrate
The prafloxacin hydrochloride dihydrate of the invention has simple operation, stable process, less energy consumption, high economy, high product yield up to more than 90 percent, high product purity up to more than 99 percent, stable preparation process and high reproducibility, and the process has short production period, improves the production efficiency, and is suitable for manufacturing and long-term storage of pharmaceutical preparations.
Drawings
FIG. 1 is an X-ray powder diffraction pattern of crystalline prafloxacin hydrochloride dihydrate of examples 1-5 of the present invention.
FIG. 2 is a DSC-TG analysis of prafloxacin hydrochloride dihydrate of examples 1-5 of the present invention.
Fig. 3 is a polarized light microscope image of prafloxacin hydrochloride dihydrate in examples 1-5 of the present invention.
Fig. 4 is a diagram showing the structure of single crystal of prafloxacin hydrochloride dihydrate in examples 1 to 5 of the present invention.
Detailed Description
The invention is described in further detail below with reference to the drawings and the detailed description. Wherein FIG. 1 is an X-ray powder diffraction pattern of the crystalline prafloxacin hydrochloride dihydrate obtained in examples 1 to 5 of the present invention; FIG. 2 is a DSC-TG analysis of prafloxacin hydrochloride dihydrate obtained in examples 1 to 5 of the present invention; FIG. 3 is a polarized light microscope image of prafloxacin hydrochloride dihydrate of examples 1-5 of the present invention; fig. 4 is a diagram showing the structure of single crystal of prafloxacin hydrochloride dihydrate in examples 1 to 5 of the present invention. The Cell number in fig. 4 is shown in the following table.
a=6.5285 b=12.9915 c=25.6615
α=90 β=90 γ=90
The foregoing examples are provided for clarity of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Example 1
(1) Dissolving 1.5g of prafloxacin in 10ml of deionized water at 25 ℃, magnetically stirring, and keeping the temperature for 15 minutes to completely dissolve and uniformly disperse the solid in the solvent; (2) 1ml of hydrochloric acid was added thereto at a feed rate of 1ml/min; (3) Continuously stirring, and culturing the crystal for 2 hours at constant temperature; (4) filtering the product, and carrying out vacuum filtration; (5) placing the obtained crystal in a drying oven at 40 ℃ for drying; (6) And drying to obtain the final prafloxacin hydrochloride dihydrate.
The X-ray powder diffraction pattern of the product has characteristic peaks at diffraction angles 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,12.4±0.2°,14.0±0.2°,15.6±0.2°,21.9±0.2°, and 29.0±0.2°. DSC showed a desolvation temperature of 60 ℃. The product appearance is light yellow powder, the purity of the product is 99.8%, and the process yield is 90.5%.
Example 2
(1) Dissolving 1.0g of prafloxacin solid in 15ml of ethanol at 28 ℃, magnetically stirring, and keeping the temperature for 15min to completely dissolve and uniformly disperse the solid in a solvent; (2) 0.5ml of hydrochloric acid was added thereto at a feed rate of 2ml/min; (3) Continuously stirring, and carrying out crystal growth at constant temperature for 3h; (4) filtering the product, and carrying out vacuum filtration; (5) placing the obtained crystal in a drying oven at 40 ℃ for drying; (6) And drying to obtain the final prafloxacin hydrochloride dihydrate.
The X-ray powder diffraction pattern of the product has characteristic peaks at diffraction angles 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,12.4±0.2°,14.0±0.2°,15.6±0.2°,21.9±0.2°, and 29.0±0.2°. DSC showed a desolvation temperature of 60 ℃. The product appearance is light yellow powder, the purity of the product is 99.5%, and the process yield is 90.2%.
Example 3
(1) Dissolving 1.5g of prafloxacin solid in 8ml of methanol at 30 ℃, magnetically stirring, and keeping the temperature for 20 minutes to ensure that the solid is completely dissolved and uniformly dispersed in a solvent; (2) 1.5ml of hydrochloric acid was added thereto at a feed rate of 3ml/min; (3) Continuously stirring, and culturing the crystal for 2 hours at constant temperature; (4) filtering the product, and carrying out vacuum filtration; (5) placing the obtained crystal in a drying oven at 35 ℃ for drying; (6) And drying to obtain the final prafloxacin hydrochloride dihydrate. The X-ray powder diffraction pattern of the product has characteristic peaks at diffraction angles 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,12.4±0.2°,14.0±0.2°,15.6±0.2°,21.9±0.2°, and 29.0±0.2°. DSC showed a desolvation temperature of 60 ℃. The product appearance is light yellow powder, the purity of the product is 99.4%, and the process yield is 90.4%.
Example 4
(1) Dissolving 1.2g of prafloxacin solid in 10ml of methanol at 40 ℃, magnetically stirring, and keeping the temperature for 15 minutes to ensure that the solid is completely dissolved and uniformly dispersed in the solvent; (2) 0.8ml of hydrochloric acid was added thereto at a feed rate of 4ml/min;
(3) Continuously stirring, and culturing the crystal for 4 hours at constant temperature; (4) filtering the product, and carrying out vacuum filtration; (5) placing the obtained crystal in a drying oven at 40 ℃ for drying; (6) And drying to obtain the final prafloxacin hydrochloride dihydrate.
The X-ray powder diffraction pattern of the product was measured at diffraction angles 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,
the characteristic peak is at 12.4+/-0.2 degrees, 14.0+/-0.2 degrees, 15.6+/-0.2 degrees, 21.9+/-0.2 degrees and 29.0+/-0.2 degrees. DSC showed a desolvation temperature of 60 ℃. The product appearance is light yellow powder, the purity of the product is 99.2%, and the process yield is 91.5%.
Example 5
(1) Dissolving 1.1g of prafloxacin solid in 5ml of deionized water at 30 ℃, magnetically stirring, and keeping the temperature for 15 minutes to completely dissolve and uniformly disperse the solid in a solvent; (2) 2ml of hydrochloric acid was added thereto at a feed rate of 4ml/min; (3) Continuously stirring, and culturing the crystal for 2 hours at constant temperature; (4) filtering the product, and carrying out vacuum filtration; (5) placing the obtained crystal in a drying oven at 40 ℃ for drying; (6) And drying to obtain the final prafloxacin hydrochloride dihydrate.
The X-ray powder diffraction pattern of the product has characteristic peaks at diffraction angles 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,12.4±0.2°,14.0±0.2°,15.6±0.2°,21.9±0.2°, and 29.0±0.2°. DSC showed a desolvation temperature of 60 ℃. The product appearance is light yellow powder, the purity of the product is 99.6%, and the process yield is 91.2%.
The invention discloses and proposes a crystal form of prafloxacin hydrochloride dihydrate and a preparation method thereof, and a person skilled in the art can properly change links such as raw materials, technological parameters and the like by referring to the content of the invention. While the methods and products of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations and modifications can be applied to the methods and products described herein to practice the techniques of this invention without departing from the spirit or scope of the invention. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be included within the spirit, scope and content of the invention.

Claims (10)

1. A crystalline prafloxacin hydrochloride dihydrate, characterized in that the crystalline prafloxacin hydrochloride dihydrate has a characteristic peak in a diffraction angle 2θ=6.9±0.2°,7.6±0.2°,9.7±0.2°,12.4±0.2°,14.0±0.2°,15.6±0.2°,21.9±0.2°,29.0±0.2°.
2. The crystalline prafloxacin hydrochloride dihydrate of claim 1 having a molecular formula of C 21 H 26 FClN 4 O 5
3. Crystals of prafloxacin hydrochloride dihydrate according to claim 1 or 2, characterized in that the crystals are desolvated at 60 ℃.
4. A process for preparing crystals of prafloxacin hydrochloride dihydrate, for preparing the crystals of any one of claims 1-3, comprising the steps of:
step 1: dissolving prafloxacin solids in water and/or ethanol until clear;
step 2: keeping the temperature of the solution obtained in the step 1 constant, and adding hydrochloric acid into the solution obtained in the step 1;
step 3: growing crystal at constant temperature;
step 4: and (3) drying the product obtained in the step (3) to obtain the final prafloxacin hydrochloride dihydrate product.
5. The process of claim 4, wherein the concentration of the prafloxacin solution after dissolution in step 1 is 0.05 to 0.15g/ml.
6. The method according to claim 4, wherein the hydrochloric acid is fed at a rate of 1ml/min to 4ml/min in step 2.
7. The method according to claim 4, wherein in the step 2, the constant temperature is 25 to 30 ℃.
8. The method according to claim 4, wherein in the step 3, the crystal growth time is 2 to 4 hours and the temperature is 25 to 30 ℃.
9. The method according to claim 4, wherein in step 4, the product obtained in step 3 is filtered, and the obtained crystals are dried in a drying oven; and drying to obtain the final prafloxacin hydrochloride dihydrate product.
10. The method according to claim 9, wherein in step 4, the drying temperature is 40 to 45 ℃ and the drying time is 2 to 4 hours.
CN202310634032.6A 2023-05-31 2023-05-31 Prafloxacin hydrochloride dihydrate crystal and preparation method thereof Pending CN116813614A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310634032.6A CN116813614A (en) 2023-05-31 2023-05-31 Prafloxacin hydrochloride dihydrate crystal and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310634032.6A CN116813614A (en) 2023-05-31 2023-05-31 Prafloxacin hydrochloride dihydrate crystal and preparation method thereof

Publications (1)

Publication Number Publication Date
CN116813614A true CN116813614A (en) 2023-09-29

Family

ID=88123236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310634032.6A Pending CN116813614A (en) 2023-05-31 2023-05-31 Prafloxacin hydrochloride dihydrate crystal and preparation method thereof

Country Status (1)

Country Link
CN (1) CN116813614A (en)

Similar Documents

Publication Publication Date Title
CN109134459B (en) Pyrroloquinoline quinone disodium salt crystal and preparation method thereof
KR101929960B1 (en) Crystalline form of ertapenem sodium and preparation method therefor
CN102268019B (en) Cefadroxil compound and preparation method thereof
US20100168117A1 (en) A process for the preparation of the stable, amorphous calcium salt of (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid
CN101967156B (en) Method for recrystallizing cefuroxime sodium
CN103755723B (en) A kind of preparation method of rifampicin I crystal form
CN113173956B (en) Preparation method of clarithromycin lactobionate
CN116813614A (en) Prafloxacin hydrochloride dihydrate crystal and preparation method thereof
WO2012126147A1 (en) Purification method of cefmetazole sodium
CN109053738B (en) Solvate of ibrutinib and preparation method thereof
CN113005161A (en) Preparation method of polysialic acid and polysialic acid product
CN110041306B (en) 4-hydroxy-2-quinolone-N- (4-quinazolinone) -3-carboxamide derivatives
WO2009121304A1 (en) Preparation of ulifloxacin optical isomer
WO2017140073A1 (en) Cefathiamidine novel crystal compound using particle process crystal product molecular assembly and morphology optimisation technology and formulation thereof
US8871927B2 (en) Method for purifying Ceftizoxime sodium
CN113527338B (en) Synthesis process of cefozopran hydrochloride
CN115710267A (en) Prafloxacin hydrate crystal and preparation method thereof
CN111072686B (en) Preparation method of cefquinome sulfate
CN114276346B (en) Isobanchamine analogue, preparation method and application of same from fleroxacin to
CN107652306B (en) Cefuroxime sodium crystal compound
CN112724159B (en) 3-vinyl-7- (thiazole methoxyimino) cephalosporanic acid crystal form and preparation method thereof
CN1290834C (en) Quinoline derivatives and their use as antibiotics
CN108864107B (en) Preparation method of indole compound with antibacterial effect
CN117024487A (en) Tilmicosin phosphate trihydrate crystal and preparation method thereof
CN109666034B (en) Lactic acid levofloxacin crystal form and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination